Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals (Nasdaq: XENE) granted equity inducement awards to eight new non-officer employees, effective October 1, 2026, to support their hiring.
The awards comprise 17,850 share options and 10,500 restricted share units (RSUs). The options have an exercise price of $38.93 per common share, equal to the closing share price on the grant date. Both award types vest over four years, subject to continued service. The board’s Compensation Committee approved the grants under the company’s Amended and Restated 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Xenon Pharmaceuticals (XENE) will present at the TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit in a virtual fireside chat on Wednesday, September 23, from 2:00 to 2:25 pm ET.
Details and webcast access will be available in the Investors section of Xenon’s website, with replays posted after the event, and the company notes that the listed date and time are subject to change. Xenon highlights its lead molecule, azetukalner, a KV7 potassium channel opener in late-stage clinical development for epilepsy, major depressive disorder and bipolar depression, and mentions additional KV7 and NaV1.7 programs in Phase 1 for pain.
Xenon Pharmaceuticals (XENE) has submitted a New Drug Application (NDA) to the U.S. FDA for azetukalner as adjunctive treatment for focal seizures in epilepsy, supported by Phase 2b X‑TOLE and Phase 3 X‑TOLE2 trials. Across both randomized, double-blind, placebo-controlled studies, all four azetukalner doses showed statistically significant reductions from baseline in monthly seizure frequency versus placebo, with a generally well-tolerated and consistent safety profile aligned with more than 1,500 patient‑years of exposure data.
Ongoing Phase 3 epilepsy trials X‑TOLE3 (focal seizures) and X‑ACKT (primary generalized tonic-clonic seizures) continue enrolling. In psychiatry, Xenon has completed enrollment in the X‑NOVA2 MDD study at about 360 patients and now expects topline data in Q1 2027. The company has voluntarily paused enrollment of new patients in its MDD and bipolar depression studies, after reviewing neuropsychiatric adverse events, while continuing treatment of currently enrolled participants and evaluating dose modifications.
Xenon Pharmaceuticals (XENE) plans to present at the Wells Fargo Healthcare Conference in Boston, MA, via a fireside chat scheduled for Wednesday, September 9, from 11:00 to 11:30 am ET.
Details and a live webcast link will be available in the Investors section of Xenon’s website, with a replay posted after the event, subject to possible schedule changes.
Xenon Pharmaceuticals (Nasdaq: XENE) granted equity inducement awards to five new non-officer employees under Nasdaq Listing Rule 5635(c)(4), effective August 27, 2026. The awards consist of an aggregate of 13,450 share options and 7,850 restricted share units (RSUs), approved by the board’s Compensation Committee.
The options have a $61.93 exercise price, equal to the August 27, 2026 closing price, a 10-year term, and vest over four years (25% at one year, then monthly thereafter). RSUs vest 25% annually over four years. All grants are made under the Amended and Restated 2025 Inducement Equity Incentive Plan.
Xenon Pharmaceuticals (Nasdaq: XENE) will present six data sets at the 16th European Epilepsy Congress (EEC) in Athens, Greece, on September 5-9, 2026. The program includes an oral presentation of topline Phase 3 X-TOLE2 efficacy and safety results for azetukalner in adults with focal onset seizures, plus multiple posters from the ongoing 7‑year X‑TOLE open-label extension covering ≥48‑month safety, long-term seizure reduction, and seizure freedom.
Additional posters will detail azetukalner’s KV7 binding, enhanced channel opening, and rational polytherapy potential, including in vivo data on additive effects with commonly prescribed antiseizure medications. Xenon will also present burden-of-illness research, early-stage NaV1.1 modulator XPC-A data in Dravet mice, and host Booth #9 and a Scientific Exhibit during EEC 2026.
Xenon Pharmaceuticals (Nasdaq: XENE) reported Q2 2026 results and a broad clinical update. The company reaffirmed plans to submit a New Drug Application for azetukalner in focal onset seizures in Q3 2026 following a pre-NDA meeting with the FDA. Phase 3 X-TOLE3 (FOS) and X-ACKT (PGTCS) enrollment is ongoing, and multiple Phase 3 neuropsychiatry studies continue, with topline X-NOVA2 MDD data expected in H1 2027.
According to Xenon, cash, cash equivalents and marketable securities totaled $1.25 billion on June 30, 2026, providing a cash runway into 2029. Q2 2026 had no revenue, research and development expenses of $99.2 million, general and administrative expenses of $23.9 million, other income of $11.8 million, and a net loss of $110.7 million, or $(1.11) per share.
Xenon Pharmaceuticals (Nasdaq: XENE) reported that its Board Compensation Committee approved equity inducement grants for eleven new non-officer employees, effective July 30, 2026, under Nasdaq Listing Rule 5635(c)(4). The grants comprise an aggregate of 32,758 share options and 19,013 restricted share units (RSUs).
The options have a 10-year term and an exercise price of $64.19 per common share, equal to Xenon’s July 30, 2026 closing price. Options vest over four years, with 25% after one year from each employee’s start date and the remainder monthly. RSUs vest 25% annually over four years from the July 30, 2026 grant date. Both awards are issued under Xenon’s Amended and Restated 2025 Inducement Equity Incentive Plan.
Xenon Pharmaceuticals (Nasdaq: XENE) will report its Q2 2026 financial results and provide a business update after the close of U.S. markets on Thursday, August 6, 2026, followed by a company presentation at 4:30 p.m. ET (1:30 p.m. PT).
Investors can access the event via live webcast on the Investors section of Xenon’s website or by dialing (800) 715-9871 (toll-free) or (646) 307-1963 (international), using conference ID 5286122. According to Xenon Pharmaceuticals, a replay will be posted after the event and the timing is subject to change.
Xenon Pharmaceuticals (Nasdaq:XENE) granted equity inducement awards to four new non-officer employees under Nasdaq Listing Rule 5635(c)(4). The grants include 20,200 share options at $60.30 and 11,850 RSUs, with four-year vesting schedules and 10-year option terms.
Xenon also highlights its lead molecule azetukalner, a KV7 potassium channel opener in Phase 3 trials for epilepsy, MDD, and BPD, plus early-stage KV7 and NaV1.7 pain programs.